Advertisement
Screener

Xencor, Inc (XNCR) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

Xencor, Inc Operating Expenses

Xencor, Inc (XNCR) reported Operating Expenses of $88.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2026-08-05

  • Xencor, Inc operating expenses for the quarter ending 2026-06-30 was $88.29M, a 14.99% increase year-over-year.
  • Xencor, Inc operating expenses for the quarter ending 2026-03-31 was $82.38M, a 8.51% increase year-over-year.
  • Xencor, Inc operating expenses for the quarter ending 2025-12-31 was $81.86M, a 24.09% increase year-over-year.
  • Xencor, Inc operating expenses for the quarter ending 2025-09-30 was $68.52M, a 6.13% decline year-over-year.
  • Xencor, Inc operating expenses for fiscal 2025 was $303.08M, a 4.91% increase from fiscal 2024.
  • Xencor, Inc operating expenses for fiscal 2024 was $288.90M, a 5.89% decline from fiscal 2023.
  • Xencor, Inc operating expenses for fiscal 2023 was $306.98M, a 24.26% increase from fiscal 2022.
  • Xencor, Inc operating expenses for fiscal 2022 was $247.05M, a 6.79% increase from fiscal 2021.
Period endOperating Expenses 3 monthOperating Expenses 3 month as first filedOperating Expenses 6 monthOperating Expenses 6 month as first filedOperating Expenses 9 monthOperating Expenses 9 month as first filedOperating Expenses 12 month
2026-06-30$88.29M
10-Q · filed 2026-08-05
$170.67M
10-Q · filed 2026-08-05
$252.53M
derived: sum of 3 quarters · filed 2026-08-05
$321.05M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$82.38M
10-Q · filed 2026-05-06
$164.24M
derived: sum of 2 quarters · filed 2026-05-06
$232.76M
derived: sum of 3 quarters · filed 2026-05-06
$309.54M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$81.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$150.38M
derived: sum of 2 quarters · filed 2026-02-25
$227.16M
derived: sum of 3 quarters · filed 2026-08-05
$303.08M
10-K · filed 2026-02-25
2025-09-30$68.52M
10-Q · filed 2025-11-05
$145.30M
derived: sum of 2 quarters · filed 2026-08-05
$221.21M
10-Q · filed 2025-11-05
$287.18M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$76.78M
10-Q · filed 2026-08-05
$152.69M
10-Q · filed 2026-08-05
$218.67M
derived: sum of 3 quarters · filed 2026-08-05
$291.66M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$75.92M
10-Q · filed 2026-05-06
$141.89M
derived: sum of 2 quarters · filed 2026-05-06
$214.88M
derived: sum of 3 quarters · filed 2026-05-06
$294.16M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$65.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$138.96M
derived: sum of 2 quarters · filed 2026-02-25
$218.24M
derived: sum of 3 quarters · filed 2026-02-25
$288.90M
10-K · filed 2026-02-25
2024-09-30$72.99M
10-Q · filed 2025-11-05
$152.27M
derived: sum of 2 quarters · filed 2025-11-05
$222.93M
10-Q · filed 2025-11-05
$301.25M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$79.28M
10-Q · filed 2025-08-06
$149.94M
10-Q · filed 2025-08-06
$228.25M
derived: sum of 3 quarters · filed 2026-02-25
$305.69M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$70.66M
10-Q · filed 2025-05-07
$148.98M
derived: sum of 2 quarters · filed 2026-02-25
$226.41M
derived: sum of 3 quarters · filed 2026-02-25
$297.93M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$78.32M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25
$155.75M
derived: sum of 2 quarters · filed 2026-02-25
$227.27M
derived: sum of 3 quarters · filed 2026-02-25
$306.98M
10-K · filed 2026-02-25
2023-09-30$77.43M
10-Q/A · filed 2025-02-24
$77.43M
10-Q · filed 2023-11-08
$148.95M
derived: sum of 2 quarters · filed 2025-02-24
$228.66M
10-Q/A · filed 2025-02-24
$227.28M
10-Q · filed 2023-11-08
$292.86M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$71.52M
10-Q/A · filed 2025-02-24
$151.22M
10-Q/A · filed 2025-02-24
$149.85M
10-Q · filed 2023-08-03
$215.43M
derived: sum of 3 quarters · filed 2025-02-27
$281.08M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$79.71M
10-Q/A · filed 2025-02-24
$78.33M
10-Q · filed 2023-05-08
$143.91M
derived: sum of 2 quarters · filed 2025-02-27
$209.56M
derived: sum of 3 quarters · filed 2025-02-27
$267.73M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$64.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$129.85M
derived: sum of 2 quarters · filed 2025-02-27
$188.03M
derived: sum of 3 quarters · filed 2025-02-27
$247.05M
10-K · filed 2025-02-27
2022-09-30$65.65M
10-Q · filed 2023-11-08
$123.82M
derived: sum of 2 quarters · filed 2023-11-08
$182.85M
10-Q · filed 2023-11-08
$245.21M
derived: sum of 4 quarters · filed 2025-02-24
2022-06-30$58.17M
10-Q · filed 2023-08-03
$117.20M
10-Q · filed 2023-08-03
$179.57M
derived: sum of 3 quarters · filed 2025-02-24
$240.55M
derived: sum of 4 quarters · filed 2025-02-24
2022-03-31$59.03M
10-Q · filed 2023-05-08
$121.39M
derived: sum of 2 quarters · filed 2025-02-24
$182.38M
derived: sum of 3 quarters · filed 2025-02-24
$240.74M
derived: sum of 4 quarters · filed 2025-02-24
2021-12-31$62.36M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-02-24
$123.35M
derived: sum of 2 quarters · filed 2025-02-24
$181.71M
derived: sum of 3 quarters · filed 2025-02-24
$231.34M
10-K/A · filed 2025-02-24
2021-09-30$60.98M
10-Q · filed 2022-11-07
$119.34M
derived: sum of 2 quarters · filed 2022-11-07
$168.98M
10-Q · filed 2022-11-07
$224.53M
derived: sum of 4 quarters · filed 2023-02-27
2021-06-30$58.36M
10-Q · filed 2022-08-03
$108.00M
10-Q · filed 2022-08-03
$163.55M
derived: sum of 3 quarters · filed 2023-02-27
$215.64M
derived: sum of 4 quarters · filed 2023-02-27
2021-03-31$49.64M
10-Q · filed 2022-05-05
$105.19M
derived: sum of 2 quarters · filed 2023-02-27
$157.28M
derived: sum of 3 quarters · filed 2023-02-27
$207.97M
derived: sum of 4 quarters · filed 2023-02-27
2020-12-31$55.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
$107.64M
derived: sum of 2 quarters · filed 2023-02-27
$158.33M
derived: sum of 3 quarters · filed 2023-02-27
$199.49M
10-K · filed 2023-02-27
2020-09-30$52.09M
10-Q · filed 2021-11-08
$102.78M
derived: sum of 2 quarters · filed 2021-11-08
$143.94M
10-Q · filed 2021-11-08
$178.03M
derived: sum of 4 quarters · filed 2022-02-24
2020-06-30$50.69M
10-Q · filed 2021-08-04
$91.85M
10-Q · filed 2021-08-04
$125.94M
derived: sum of 3 quarters · filed 2022-02-24
$161.98M
derived: sum of 4 quarters · filed 2022-02-24
2020-03-31$41.16M
10-Q · filed 2021-05-05
$75.25M
derived: sum of 2 quarters · filed 2022-02-24
$111.29M
derived: sum of 3 quarters · filed 2022-02-24
$150.34M
derived: sum of 4 quarters · filed 2022-02-24
2019-12-31$34.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$70.13M
derived: sum of 2 quarters · filed 2022-02-24
$109.18M
derived: sum of 3 quarters · filed 2022-02-24
$142.88M
10-K · filed 2022-02-24
2019-09-30$36.04M
10-Q · filed 2020-11-06
$75.09M
derived: sum of 2 quarters · filed 2020-11-06
$108.79M
10-Q · filed 2020-11-06
$141.44M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$39.06M
10-Q · filed 2020-08-05
$72.75M
10-Q · filed 2020-08-05
$105.40M
derived: sum of 3 quarters · filed 2021-02-24
$133.79M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31$33.70M
10-Q · filed 2020-05-08
$66.34M
derived: sum of 2 quarters · filed 2021-02-24
$94.73M
derived: sum of 3 quarters · filed 2021-02-24
$123.02M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31$32.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$61.03M
derived: sum of 2 quarters · filed 2021-02-24
$89.33M
derived: sum of 3 quarters · filed 2021-02-24
$119.97M
10-K · filed 2021-02-24
2018-09-30$28.39M
10-Q · filed 2019-11-05
$56.68M
derived: sum of 2 quarters · filed 2019-11-05
$87.33M
10-Q · filed 2019-11-05
$112.15M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30$28.29M
10-Q · filed 2019-08-07
$58.94M
10-Q · filed 2019-08-07
$83.76M
derived: sum of 3 quarters · filed 2020-02-25
$107.34M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31$30.65M
10-Q · filed 2019-05-09
$55.47M
derived: sum of 2 quarters · filed 2020-02-25
$79.05M
derived: sum of 3 quarters · filed 2020-02-25
$100.06M
derived: sum of 4 quarters · filed 2020-02-25
2017-12-31$24.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$48.40M
derived: sum of 2 quarters · filed 2020-02-25
$69.41M
derived: sum of 3 quarters · filed 2020-02-25
$89.27M
10-K · filed 2020-02-25
2017-09-30$23.58M
10-Q · filed 2018-11-05
$44.59M
derived: sum of 2 quarters · filed 2018-11-05
$64.45M
10-Q · filed 2018-11-05
$80.92M
derived: sum of 4 quarters · filed 2019-02-26
2017-06-30$21.01M
10-Q · filed 2018-08-07
$40.87M
10-Q · filed 2018-08-07
$57.34M
derived: sum of 3 quarters · filed 2019-02-26
$74.41M
derived: sum of 4 quarters · filed 2019-02-26
2017-03-31$19.86M
10-Q · filed 2018-05-07
$36.33M
derived: sum of 2 quarters · filed 2019-02-26
$53.40M
derived: sum of 3 quarters · filed 2019-02-26
$70.85M
derived: sum of 4 quarters · filed 2019-02-26
2016-12-31$16.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$33.54M
derived: sum of 2 quarters · filed 2019-02-26
$50.99M
derived: sum of 3 quarters · filed 2019-02-26
$64.98M
10-K · filed 2019-02-26
2016-09-30$17.08M
10-Q · filed 2017-11-08
$34.53M
derived: sum of 2 quarters · filed 2017-11-08
$48.51M
10-Q · filed 2017-11-08
$62.83M
derived: sum of 4 quarters · filed 2018-02-28
2016-06-30$17.45M
10-Q · filed 2017-08-07
$31.44M
10-Q · filed 2017-08-07
$45.75M
derived: sum of 3 quarters · filed 2018-02-28
$59.57M
derived: sum of 4 quarters · filed 2018-02-28
2016-03-31$13.98M
10-Q · filed 2017-05-10
$28.30M
derived: sum of 2 quarters · filed 2018-02-28
$42.12M
derived: sum of 3 quarters · filed 2018-02-28
$52.12M
derived: sum of 4 quarters · filed 2018-02-28
2015-12-31$14.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28
$28.13M
derived: sum of 2 quarters · filed 2018-02-28
$38.13M
derived: sum of 3 quarters · filed 2018-02-28
$46.10M
10-K · filed 2018-02-28
2015-09-30$13.81M
10-Q · filed 2016-11-02
$23.82M
derived: sum of 2 quarters · filed 2016-11-02
$31.78M
10-Q · filed 2016-11-02
$38.80M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$10.00M
10-Q · filed 2016-08-03
$17.97M
10-Q · filed 2016-08-03
$24.98M
derived: sum of 3 quarters · filed 2017-03-01
$32.12M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$7.97M
10-Q · filed 2016-05-02
$14.98M
derived: sum of 2 quarters · filed 2017-03-01
$22.12M
derived: sum of 3 quarters · filed 2017-03-01
$28.00M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$7.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$14.15M
derived: sum of 2 quarters · filed 2017-03-01
$20.03M
derived: sum of 3 quarters · filed 2017-03-01
$25.98M
10-K · filed 2017-03-01
2014-09-30$7.13M
10-Q · filed 2015-11-04
$13.01M
derived: sum of 2 quarters · filed 2015-11-04
$18.96M
10-Q · filed 2015-11-04
$24.42M
derived: sum of 4 quarters · filed 2016-03-08
2014-06-30$5.88M
10-Q · filed 2015-08-05
$11.83M
10-Q · filed 2015-08-05
$17.28M
derived: sum of 3 quarters · filed 2016-03-08
$22.29M
derived: sum of 4 quarters · filed 2016-03-08
2014-03-31$5.95M
10-Q · filed 2015-05-05
$11.40M
derived: sum of 2 quarters · filed 2016-03-08
$16.41M
derived: sum of 3 quarters · filed 2016-03-08
$21.34M
derived: sum of 4 quarters · filed 2016-03-08
2013-12-31$5.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08
$10.46M
derived: sum of 2 quarters · filed 2016-03-08
$15.39M
derived: sum of 3 quarters · filed 2016-03-08
$20.69M
10-K · filed 2016-03-08
2013-09-30$5.00M
10-Q · filed 2014-11-10
$9.93M
derived: sum of 2 quarters · filed 2014-11-10
$15.24M
10-Q · filed 2014-11-10
2013-06-30$4.93M
10-Q · filed 2014-08-01
$10.23M
10-Q · filed 2014-08-01
2013-03-31$5.31M
10-Q · filed 2014-05-15
2012-12-31$15.75M
10-K · filed 2015-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Septerna, Inc. (SEPN)United States$1.783B-63.01
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
COMPASS Pathways plc (CMPS)$1.812B-4.87
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82